COVID-19 outcomes described in children with rheumatic diseases taking biologics
medwireNews: An analysis of children with rheumatic diseases undergoing treatment with biologic agents has found no severe cases of COVID-19.
The Russian study, presented at the online British Society for Rheumatology 2021 Annual Conference, included 118 children (76% girls) with various rheumatic diseases, the majority of whom had a diagnosis of juvenile idiopathic arthritis (88%). The most commonly prescribed biologic was etanercept (34%), followed by adalimumab (28%) and tocilizumab (20%); most patients (79%) were also taking methotrexate.
Nadezhda Tsurikova (Children's Clinical Regional Hospital, Rostov-on-Don, Russian Federation) reported that four of the children had flu-like symptoms and a positive polymerase chain reaction (PCR) test for COVID-19.
Among the 10 patients who had documented contact with a person with COVID-19, two had flu-like symptoms and tested positive, one was asymptomatic and tested positive, while the remaining seven were asymptomatic and tested negative. None of the patients with COVID-19 developed SARS-CoV-2 pneumonia.
Although there were “no registered severe cases of COVID-19” in the study, Tsurikova cautioned that “further follow-up is needed to better understand the risk and impact of COVID-19 among children with rheumatic diseases […] receiving therapy with biological agents.”
medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group
29 April 2021: The coronavirus pandemic is affecting all healthcare professionals across the globe. Medicine Matters’ focus, in this difficult time, is the dissemination of the latest data to support you in your research and clinical practice, based on the scientific literature. We will update the information we provide on the site, as the data are published. However, please refer to your own professional and governmental guidelines for the latest guidance in your own country.